Ken Reali, president and CEO of TranS1, attributes the company’s 26 percent decrease in quarterly revenue to ongoing physician reimbursement pressures. The company experienced a decrease in procedure volume of its AxiaLIF, which recently had three peer reviewed clinical studies accepted for publication. The company also launched two new products during this quarter, which expand the product portfolio.
Domestic revenues were $4.9 million during the second quarter of 2011, a decrease from the $6.7 million reported during the second quarter of 2010.Net loss also increased from $3.6 million last year to $4.3 million this year.
Read the release on TranS1.
Related Articles on Orthopedic Device Companies:
MAKO Surgical 2Q Revenue Reaches $18.6M, 81% Increase
Alphatec Holdings Reports 2Q Revenue of $50.9M, 12% Increase
Wright Medical Group Reports 4% Net Sales Increase Driven by International Market Growth
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
